These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9505989)

  • 21. [Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients. Interaction with plasma levels].
    Baño MD; Micó JA; Agujetas M; López ML; Guillén JL
    Actas Esp Psiquiatr; 2001; 29(4):215-20. PubMed ID: 11470055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability.
    Silke B; Campbell C; King DJ
    J Psychopharmacol; 2002 Dec; 16(4):355-60. PubMed ID: 12503835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
    Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
    Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
    Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
    Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similarity of clozapine's and olanzapine's acute effects on rats' lapping behavior.
    Das S; Fowler SC
    Psychopharmacology (Berl); 1996 Feb; 123(4):374-8. PubMed ID: 8867877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe akathisia during olanzapine treatment of acute schizophrenia.
    Jauss M; Schröder J; Pantel J; Bachmann S; Gerdsen I; Mundt C
    Pharmacopsychiatry; 1998 Jul; 31(4):146-8. PubMed ID: 9754850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers.
    Beuzen JN; Taylor N; Wesnes K; Wood A
    J Psychopharmacol; 1999; 13(2):152-8. PubMed ID: 10475721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.
    Nyberg S; Farde L; Halldin C
    Neuropsychopharmacology; 1997 Jan; 16(1):1-7. PubMed ID: 8981383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.
    Olesen OV; Linnet K
    Ther Drug Monit; 1999 Feb; 21(1):87-90. PubMed ID: 10051059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration.
    Markowitz JS; DeVane CL
    J Clin Psychopharmacol; 1999 Jun; 19(3):289-91. PubMed ID: 10350045
    [No Abstract]   [Full Text] [Related]  

  • 31. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.
    Hägg S; Spigset O; Lakso HA; Dahlqvist R
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia.
    Kando JC; Shepski JC; Satterlee W; Patel JK; Reams SG; Green AI
    Ann Pharmacother; 1997 Nov; 31(11):1325-34. PubMed ID: 9391688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine overdose with serum concentrations.
    Cohen LG; Fatalo A; Thompson BT; Di Centes Bergeron G; Flood JG; Poupolo PR
    Ann Emerg Med; 1999 Aug; 34(2):275-8. PubMed ID: 10424935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo.
    Sharpley AL; Vassallo CM; Cowen PJ
    Biol Psychiatry; 2000 Mar; 47(5):468-70. PubMed ID: 10704958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine.
    Licht RW; Olesen OV; Friis P; Laustsen T
    J Clin Psychopharmacol; 2000 Feb; 20(1):110-2. PubMed ID: 10653223
    [No Abstract]   [Full Text] [Related]  

  • 37. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection.
    Aravagiri M; Ames D; Wirshing WC; Marder SR
    Ther Drug Monit; 1997 Jun; 19(3):307-13. PubMed ID: 9200772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
    Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
    Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioreceptor binding profile of the atypical antipsychotic olanzapine.
    Bymaster FP; Calligaro DO; Falcone JF; Marsh RD; Moore NA; Tye NC; Seeman P; Wong DT
    Neuropsychopharmacology; 1996 Feb; 14(2):87-96. PubMed ID: 8822531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.